TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology business aiming to improve outcomes for patients with solid tumors. The company integrates its innovative delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist. TriSalus's technology addresses two main challenges in treating solid tumors: high intratumoral pressure, which restricts therapeutic delivery, and off-target delivery. Nelitolimod, combined with their technology, specifically targets the immunosuppressive properties of tumor immune cells in liver, pancreas, and other solid tumors. Many solid tumors, particularly desmoplastic tumors like pancreatic ductal adenocarcinoma ("PDAC"), liver tumors, and various other types, have high interstitial fluid pressure and disorganized, leaky blood vessels, which hinder therapeutic penetration and distribution. TriSalus's platform approach, Pressure-Enabled Drug Delivery ("PEDD"), modulates pressure and flow within blood vessels to enhance intravascular therapeutic delivery into tumors, aiming to increase tumor response compared to conventional delivery methods. The company's device business, including PEDD and TriNav, shows potential for growth.